Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S. Hohaus is active.

Publication


Featured researches published by S. Hohaus.


British Journal of Haematology | 1997

Factors influencing collection of peripheral blood progenitor cells following high‐dose cyclophosphamide and granulocyte colony‐stimulating factor in patients with multiple myeloma

Hartmut Goldschmidt; Ute Hegenbart; M. Wallmeier; S. Hohaus; Rainer Haas

We treated 103 multiple myeloma (MM) patients with 7 g/m2 cyclophosphamide (Cy) followed by 300 μg G‐CSF/d to harvest peripheral blood progenitor cells (PBPC). PBPC autografts containing > 2.0 × 106 CD34+ cells per kg body weight were obtained at the first attempt from 90/100 evaluable patients. The most significant factor predicting impairment of PBPC collection was the duration of previous melphalan treatment (P < 0.0001). In multivariate discriminate analysis, treatment with melphalan during the most recent chemotherapy cycles prior to mobilization (P = 0.0727) and previous radiotherapy (P = 0.0628) had a marginally significant negative influence on the efficacy of PBPC collection. We found no reduced functional capacity of CD34+ cells to restore haemopoiesis after myeloablative treatment related to the duration of melphalan exposure. At the time of best response to conventional treatment, a median paraprotein reduction of 21% was achieved following high‐dose cyclophosphamide (HD‐Cy). Two heavily pretreated patients died and one patient developed pulmonary toxicity W.H.O. grade IV following HD‐Cy. Potential transplant candidates should undergo mobilization and harvesting of PBPC before melphalan‐containing treatment. Combinations of haemopoietic growth factors and their dose modifications should be investigated to improve PBPC collection, to allow a dosage reduction of the mobilization chemotherapy.


British Journal of Haematology | 1999

Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content

Maria Teresa Voso; S. Hohaus; Marion Moos; Margit Pförsich; Friedrich W. Cremer; Richard F. Schlenk; Simona Martin; Ute Hegenbart; Hartmut Goldschmidt; Rainer Haas

The efficacy of an immunomagnetic purging method and the Isolex 300 devices were assessed for selecting CD34+ cells from leukapheresis products of 29 patients with non‐Hodgkins lymphoma (NHL), 39 with multiple myeloma and 34 with breast cancer. The mean purity of the CD34+ cell population was 93.6% and the mean recovery was 67.7%. Following enzymatic cleavage by chymopapain the expression of Thy‐1 and Leu‐8 was significantly reduced without affecting haematological recovery. The population of selected CD34+ cells of 4/8 patients with follicular lymphoma became PCR‐negative. A 2.5 log reduction of tumour cells could be achieved in four patients with multiple myeloma as shown by a quantitative PCR assay. There were no tumour cells detectable in any of the 19 CD34+ cell preparations of patients with breast cancer. In 64 patients who received 94 cycles of high‐dose therapy, a mean number of 4.7 × 106 CD34+ cells/kg were autografted. The time needed for platelet reconstitution was different when a comparison was made with 156 patients, who had received unmanipulated leukapheresis products (10 v 12 d, P = 0.006). No significant differences with regard to neutrophil recovery were noted. Five patients had a graft failure. Two of them died (on day 78 and 88 following PBSCT), and three patients were rescued with unmanipulated back‐up transplants. In conclusion, the immunomagnetic selection of CD34+ cells provides autografts with reduced tumour cell content and an engraftment ability similar to that of unmanipulated autografts.


British Journal of Haematology | 1997

Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer

S. Hohaus; Margit Pförsich; Simona Murea; Alhossain Abdallah; Yung‐Sheng Lin; Liane Funk; M. T. Voso; Sepp Kaul; Hans Schmid; Diethelm Wallwiener; Rainer Haas

Contamination of transplants with tumour cells may contribute to relapse after peripheral blood stem cell transplantation (PBSCT). We studied the feasibility of CD34+ cell selection from blood‐derived autografts obtained following G‐CSF‐supported cytotoxic chemotherapy in a group of 25 patients with breast cancer (10 with high‐risk stage II/III and 15 with stage IV without bone or bone marrow involvement).


European Journal of Cancer | 1997

Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer

Rainer Haas; H. Schmid; Uwe Hahn; S. Hohaus; Hartmut Goldschmidt; Simona Murea; Manfred Kaufmann; Michael Wannenmacher; Diethelm Wallwiener; G. Bastert; Werner Hunstein

We evaluated the therapeutic efficacy and toxicity of a tandem high-dose therapy with peripheral blood stem cell (PBSC) support in 40 patients with high-risk, primary breast cancer (stage II-III) and involvement of ten or more positive axillary lymph nodes. Their median age was 44 years (range 23-56). Two cycles of cytotoxic chemotherapy with ifosfamide (10000 mg/m2) and epirubicin (100 mg/m2) were administered. Granulocyte colony-stimulating factor (G-CSF) was given to hasten neutrophil reconstitution and to mobilise PBSC during marrow recovery. Leukaphereses were performed following the first and/or second cycle. Tandem high-dose therapy consisted of two cycles with ifosfamide (15 or 12 g/m2) and epirubicin (150 mg/m2), while carboplatin (900 mg/m2) was added for the last 24 patients included. Using an immunocytochemical method, two of 11 patients had cytokeratin-positive tumour cells in three leukapheresis products that were collected following the first G-CSF-supported cycle with ifosfamide and epirubicin, whereas only two harvests obtained following the second cycle in 26 patients contained cytokeratin-positive tumour cells. The number of CD34+ cells/kg re-infused following both high-dose cycles was similar (4.20 +/- 0.29 x 10(6), first cycle and 5.25 +/- 0.63 x 10(6), second cycle), and no notable difference was noted in the speed of haematological reconstitution. An absolute neutrophil count (ANC) of 0.5 x 10(9)/1 was reached after a median time of 13 days, while an unsupported platelet count of 20.0 x 10(9)/1 was achieved after a median time of 8 (first cycle) and 9 (second cycle) days post-transplantation. Patients autografted with more than 7.5 x 10(6) CD34+ cells/kg had platelet counts above 20 x 10(9)/1 within less than 10 days. 6 patients relapsed between 7 and 11 months (median 8 months) post-transplantation. 37 patients are alive and in remission with a median follow-up time of 11 months (range 1-38). This translates into a probability of disease-free survival (DFS) of 77% (95% CI 32-95%) at 38 months. The probability of overall survival is 85%, since 3 patients with local relapse achieved a second complete remission following surgery and involved-field radiotherapy. In conclusion, a sequential high-dose therapy including ifosfamide, epirubicin, carboplatin and PBSC support is well tolerated and effective in patients with high-risk primary breast cancer. Involved-field irradiation should be performed post-transplantation to reduce the risk of local relapse.


Recent results in cancer research | 1998

Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma Following High-Dose Melphalan-Based Therapy

Hartmut Goldschmidt; Ute Hegenbart; M. Wallmeier; S. Hohaus; R. Engenhart; Michael Wannenmacher; Rainer Haas

The objective of our study was to evaluate the efficacy and toxicity of a high-dose melphalan-based therapy with or without total body irradiation (TBI) followed by peripheral blood progenitor cell (PBPC) transplantation in patients with multiple myeloma. Between June 1992 and June 1996, 104 patients (71 male, 33 female) with a median age of 51 years (range 30-65 years) underwent transplantation at our center. PBPC were mobilized using high-dose chemotherapy followed by treatment with G-CSF. Fifty patients were treated with TBI+melphalan 140 mg/m2 while 54 patients received melphalan 200 mg/m2. Following PBPC autografting, the median time to attainment of platelets > or = 20 x 10(9)/l and neutrophils > or = 0.5 x 10(9)/l was 11 and 14 days, with no difference between the treatment groups. In the TBI group significantly longer periods of total parenteral nutrition were required due to the occurrence of severe mucositis. Two patients from the TBI group died of transplantation-related complications. Following high-dose treatment, remission state improved in 43 out of 102 patients. No statistically significant advantage in reaching complete or partial remission was observed with TBI+high-dose melphalan compared to the treatment with high-dose melphalan alone. The optimal high-dose treatment, with particular reference to the inclusion or omission of TBI, should be prospectively investigated.


British Journal of Haematology | 1996

HIGH‐DOSE THERAPY WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION RESULTS IN A SIGNIFICANT REDUCTION OF THE HaEMOPOIETIC PROGENITOR CELL COMPARTMENT

M. T. Voso; Simona Murea; Hartmut Goldschmidt; S. Hohaus; Rainer Haas

In order to study the effect of high‐dose therapy with peripheral blood stem cell transplantation (PBSCT) on the haemopoietic reserve in man, the number and composition of bone marrow (BM) and peripheral blood (PB)‐derived progenitor cells were examined in 137 cancer patients. In 45 patients, paired samples from BM and PB were obtained before PBSC mobilization and 6–27 months after transplantation. Following PBSCT, the proportion of CD34+ cells was significantly smaller than before mobilization (BM 1.99±0.24 versus 0.8±0.09, P<0.001), and no change was observed at several follow‐up visits thereafter.


Journal of Cancer Research and Clinical Oncology | 1998

Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer

J. Huober; A. Schneeweiss; S. Hohaus; G. Wittmann; A. Meyer; S. Martin; Hartmut Goldschmidt; G. Bastert; Rainer Haas; Diethelm Wallwiener

Abstract The purpose of this phase II study was to evaluate the therapeutic efficacy and toxicity of a tandem or triple high-dose chemotherapy (HDC) with autologous peripheral blood stem cell transplantation (PBSCT) in patients with metastatic breast cancer (MBC) as first line chemotherapy. Conventional chemotherapy consisted of two cycles of epirubicin 120 mg/m2 and ifosfamide 7500 mg/m2 in the case of tandem HDC and one cycle of paclitaxel 135 mg/m2, epirubicin 90 mg/m2 and ifosfamide 6000 mg/m2 in the case of triple HDC. Tandem HDC was composed of two cycles of epirubicin 180 mg/m2, ifosfamide 12000 mg/m2 and carboplatin 900 mg/m2. In the case of triple HDC, paclitaxel 180 mg/m2, etoposide 1500 mg/m2 and thiotepa 600 mg/m2 was added as the third cycle. Patients with tandem HDC (n = 20) were evaluable for both survival and toxicity, and patients with triple HDC (n = 21) only for toxicity because of short-term follow-up. Both tandem and triple HDC were well tolerated and could be safely administered. Non-hematological WHO grade 3 or 4 toxicities were mucositis (8), temporary renal insufficiency (1), myocardial infarction (1), and neuropathy (1). No toxic death occurred. The Kaplan-Meier estimates for 44-months without progression and the overall survival were 12% and 38% respectively. The median survival was 22 months (95% CI: 7.4–51.7 months) and the median progression-free interval 14 months (95% CI: 5.1–43.7 months). In a population with an unfavorable prognosis, tandem HDC showed similar efficacy as to that described in other phase II studies. Triple HDC seems not to improve patient outcome compared to tandem HDC, but a long-term follow up is required.


Stem Cells | 2001

Comparison of Double and Triple High‐Dose Chemotherapy with Autologous Blood Stem Cell Transplantation in Patients with Metastatic Breast Cancer

Andreas Schneeweiss; Manfred Hensel; Ronald Goerner; T. Khbeis; S. Hohaus; Gerlinde Egerer; Erich Solomayer; Rainer Haas; Eva-Maria Grischke; G. Bastert; Anthony D. Ho

In patients with metastatic breast cancer (MBC), early dose intensification with multiple cycles of peripheral blood stem cell‐supported high‐dose chemotherapy (HDCT) seems superior to a late dose‐intensification strategy. We compared the progression‐free survival (PFS) and overall survival (OS) of 20 patients treated with a double (D)‐HDCT regimen to 20 patients who received a triple (T)‐HDCT, matched by age, estrogen receptor (ER) status, adjuvant chemotherapy, initial disease‐free interval, predominant metastatic site, and number of metastatic sites. At a median follow‐up of 41.5 months (range, 14‐88 months) an intent‐to‐treat analysis showed no difference in PFS (p = 0.72) and OS (p = 0.93) between the matched patients. For all 76 patients treated within the D‐ or T‐HDCT trial, median PFS and OS was 13 months (range, 2‐78 months) and 24.5 months (range, 7‐78 months), respectively. In multivariate analysis independent predictors of shorter OS included negative ER (relative risk [RR] = 3.0 [95% confidence interval (CI) 1.5‐5.9]; p = 0.002), more than two metastatic sites (RR = 2.4 [95% CI 1.0‐5.7]; p = 0.049) and failure to achieve complete remission/no evidence of disease (CR/NED) after HDCT (RR = 4.5 [95% CI 2.0‐10.1]; p < 0.0001). These data show that early dose intensification with T‐HDCT is not superior to a D‐HDCT regimen in patients with MBC. ER‐negative tumors, more than two metastatic sites and no CR/NED after HDCT, are associated with inferior outcome.


Annals of Hematology | 2000

High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors

Kai Neben; S. Hohaus; H. Goldschmidt; Gerlinde Egerer; M. T. Voso; A. D. Ho; Rainer Haas

Abstract From March 1986 to March 1998, 82 patients with relapsed or refractory Hodgkins disease underwent high-dose chemotherapy (HDCT) with peripheral blood stem cell (PBSC) transplantation in our center. This is a retrospective analysis of the long-term clinical outcome. There were 52 males and 30 females with a median age of 32 years (range 18–59 years). Prior to transplantation, 36 patients were in complete remission (CR), 34 in partial remission (PR), and 12 had refractory disease after salvage therapy. For HDCT, 78 patients were treated with CBV (cyclophosphamide, 6.0–6.8 g/m2; etoposide, 1.0–1.6 g/m2; carmustine, 0.45–0.8 g/m2), while four patients received different regimens. Probability of freedom from progression (FFP), overall survival (OS), and event-free survival (EFS) at 5 years of the entire group was 63%, 61%, and 54%, respectively. Early mortality rate (≤100 days) declined from 17% to 6% after 1992. Five patients died of late transplant-related complications (>100 days), including secondary lymphoma and leukemia in two patients. None of the refractory patients survived beyond 3.5 years. Multivariate analyses identified extranodal sites of disease at relapse and refractory disease status prior to transplantation as significant prognostic factors for FFP, EFS, and OS. As we have shown in our study, remarkable progress was achieved in reducing early morbidity and mortality over time, but this was associated with only a slight, not significant improvement of long-term outcome (OS 66% vs 57% at 5 years for patients undergoing PBSC transplantation before and after 1992, P=0.26). Although the results as a whole are encouraging for chemosensitive patients, new therapeutic strategies are needed to reduce toxicity and improve the clinical outcome of patients, especially of those with a less favorable prognosis.


Cancer Chemotherapy and Pharmacology | 1999

Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer.

S. Hohaus; S. Martin; A. Schneeweiss; M. T. Voso; Richard F. Schlenk; Diethelm Wallwiener; G. Bastert; Rainer Haas

Abstract We report on the efficacy and toxicity of a sequential high-dose therapy with peripheral blood stem cell (PBSC) support in 107 patients with high-risk stage II/III breast cancer. There were 90 patients with more than 9 tumour-positive axillary lymph nodes. An induction therapy of two cycles of ifosfamide (total dose, 7,500 mg/m2) and epirubicin (120 mg/m2) was given, and PBSC were harvested during granulocyte colony-stimulating factor (G-CSF)-supported leukocyte recovery following the second cycle. The PBSC-supported high-dose chemotherapy consisted of two cycles of ifosfamide (total dose 12,000 mg/m2), carboplatin (900 mg/m2) and epirubicin (180 mg/m2). Patients were autografted with a median number of 4.1 × 106 CD34+ cells/kg (range 1.9–26.5 × 106), resulting in haematological reconstitution within approximately 2 weeks following high-dose therapy. The toxicity was moderate in general, and there was no treatment-related toxic death. Twenty-nine patients (27.1% of all patients) relapsed between 3 and 46 months following the last cycle of high-dose therapy (median 15 months). The probability of disease-free and overall survival at 3 years was 56% and 83%, respectively. A multivariate analysis showed that patients with stage II disease had a significantly better probability of disease-free survival (71%) in comparison with patients with stage III disease (30%). The probability of disease-free survival was also significantly better for patients with oestrogen receptor-positive tumours (62%) compared with patients with receptor-negative ones (40%). In conclusion, sequential high-dose chemotherapy with PBSC support can be safely administered to patients with high-risk stage II/III breast cancer. Further intensification of the therapy including the addition of non-cross-resistant drugs or immunological approaches may be envisaged for patients with stage III disease and hormone receptor-negative tumours.

Collaboration


Dive into the S. Hohaus's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maria Teresa Voso

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giuseppe Leone

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

B. Witt

Heidelberg University

View shared research outputs
Researchain Logo
Decentralizing Knowledge